Novozymes: More challenging than we expected
The great hope in Novozymes’ pharma division, hyaluronic acid, has yet to generate convincing sales numbers. The company sheds light on the reasons for that.
by Stefan Singh Kailay
In Tianjin in China there is a factory, a factory that cost USD 65 million, a factory erected by the Danish company Novozymes with a view to supporting the company’s new focus on hyaluronic acid.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Analyst: Novozymes underestimates one thing
For abonnenter
Novozymes in collaboration with US biotech company
For abonnenter
Novozymes’ biopharma-sales cut in half
For abonnenter
